These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 22541588)

  • 1. Failure to intensify hypertension therapy after rejected aliskiren claims.
    Zeng F; Park J; Plauschinat CA; Patel BV
    Clin Ther; 2012 May; 34(5):1122-31. PubMed ID: 22541588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry.
    Zeymer U; Dechend R; Deeg E; Kaiser E; Senges J; Pittrow D; Schmieder R;
    Int J Clin Pract; 2012 Mar; 66(3):251-61. PubMed ID: 22321062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication adherence before an increase in antihypertensive therapy: a cohort study using pharmacy claims data.
    Grant RW; Singer DE; Meigs JB
    Clin Ther; 2005 Jun; 27(6):773-81. PubMed ID: 16117984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy.
    Yokoyama K; Yang W; Preblick R; Frech-Tamas F
    J Manag Care Pharm; 2007 Apr; 13(3):235-44. PubMed ID: 17407390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
    Drummond W; Sirenko YM; Ramos E; Baek I; Keefe DL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):327-33. PubMed ID: 21846154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive medication changes and blood pressure goal achievement in a managed care population.
    Engel-Nitz NM; Darkow T; Lau H
    J Hum Hypertens; 2010 Oct; 24(10):659-68. PubMed ID: 20107489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension.
    Kushiro T; Itakura H; Abo Y; Gotou H; Terao S; Keefe DL
    Hypertens Res; 2009 Mar; 32(3):169-75. PubMed ID: 19262478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive effectiveness of aliskiren for the 'real-world' management of hypertension: multilevel modelling of 180-day blood pressure outcomes (the Belgian DRIVER Study).
    Verpooten GA; Aerts A; Coen N; Vancayzeele S; Hermans C; Bowles J; MacDonald K; Abraham I; Lee CS
    Int J Clin Pract; 2011 Jan; 65(1):54-63. PubMed ID: 21155943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aliskiren: new drug. Arterial hypertension: no evidence of clinical efficacy.
    Prescrire Int; 2008 Apr; 17(94):47-50. PubMed ID: 18516803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
    Yarows SA; Oparil S; Patel S; Fang H; Zhang J
    Adv Ther; 2008 Dec; 25(12):1288-302. PubMed ID: 19066757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aliskiren: renin inhibitor for hypertension management.
    Cheng JW
    Clin Ther; 2008 Jan; 30(1):31-47. PubMed ID: 18343241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
    Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of aliskiren in a 'real-life' model of hypertension management: analysis of national Web-based drug-monitoring system in Italy.
    Volpe M; Tocci G; Bianchini F; De Rosa M; Fedozzi E; Covezzoli A; Maggioni AP;
    J Hypertens; 2012 Jan; 30(1):194-203. PubMed ID: 22157325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of high- and low-sodium diets on ambulatory blood pressure in patients with hypertension receiving aliskiren.
    Weir MR; Yadao AM; Purkayastha D; Charney AN
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):356-63. PubMed ID: 20876343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-year treatment adherence among outpatients initiating antihypertensive medication in Korea: results of a retrospective claims review.
    Sung SK; Lee SG; Lee KS; Kim DS; Kim KH; Kim KY
    Clin Ther; 2009 Jun; 31(6):1309-20. PubMed ID: 19695396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
    Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients.
    Siddiqi L; Oey PL; Blankestijn PJ
    Nephrol Dial Transplant; 2011 Sep; 26(9):2930-4. PubMed ID: 21467128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient characteristics and prescription fill patterns for allergic rhinitis medications, with a focus on montelukast, in a commercially insured population.
    Bollinger ME; Diette GB; Chang CL; Stephenson JJ; Sajjan SG; Fan T; Allen-Ramey FC
    Clin Ther; 2010 Jun; 32(6):1093-102. PubMed ID: 20637964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.
    Andersen K; Weinberger MH; Egan B; Constance CM; Wright M; Lukashevich V; Keefe DL
    Cardiovasc Ther; 2010 Dec; 28(6):344-9. PubMed ID: 20406241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.